CPHOA Stock Overview
Engages in the development, cultivation, and distribution of recreational and medical cannabis products in Europe, Canada, Australia, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Melodiol Global Health Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.002 |
| 52 Week High | AU$0.029 |
| 52 Week Low | AU$0.002 |
| Beta | 2.61 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| CPHOA | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 0% | -4.6% | 0.7% |
| 1Y | n/a | 61.3% | 11.4% |
Return vs Industry: Insufficient data to determine how CPHOA performed against the Australian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how CPHOA performed against the Australian Market.
Price Volatility
| CPHOA volatility | |
|---|---|
| CPHOA Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in AU Market | 16.9% |
| 10% least volatile stocks in AU Market | 3.3% |
Stable Share Price: CPHOA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CPHOA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | Will Lay | melodiolglobalhealth.com |
Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, North America, and the Asia Pacific. The company develops and commercializes therapeutic products; and cultivates, processes, and sells cannabis products, as well as supplies cannabis retail products. Its products include anibidiol, a complementary feed product for companion animals; cannaQIX, a nutraceutical product containing hemp oil extract, and vitamins and zinc that reduces stress and supports psychological and nervous functions; and topical and skin care products, which include cannaDOL, a CBD-based topical gel associated with a mixture of cooling and warming essential oils.
Melodiol Global Health Limited Fundamentals Summary
| CPHOA fundamental statistics | |
|---|---|
| Market cap | AU$31.85m |
| Earnings (TTM) | -AU$18.15m |
| Revenue (TTM) | AU$7.53m |
4.2x
P/S Ratio-1.8x
P/E RatioIs CPHOA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CPHOA income statement (TTM) | |
|---|---|
| Revenue | AU$7.53m |
| Cost of Revenue | AU$6.10m |
| Gross Profit | AU$1.43m |
| Other Expenses | AU$19.58m |
| Earnings | -AU$18.15m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0086 |
| Gross Margin | 18.95% |
| Net Profit Margin | -241.13% |
| Debt/Equity Ratio | 0% |
How did CPHOA perform over the long term?
See historical performance and comparison